MedPath

Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease

Not Applicable
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Device: NIOV - Room Air
Device: NIOV - Oxygen
Device: Nasal Cannula Oxygen
Registration Number
NCT01372462
Lead Sponsor
Breathe Technologies, Inc.
Brief Summary

Pilot study in 15 stable male subjects with severe-to-very severe Chronic Obstructive Pulmonary Disease (COPD) to evaluate the effects of short term use of the Breathe Technologies noninvasive open ventilation (NIOV) system on respiratory mechanics during constant work rate exercise in subjects with severe COPD.

Detailed Description

Study was a randomized double-blinded crossover design in which subjects completed a series of exercises at a constant work rate while using 1) Test noninvasive ventilation (NIOV) system powered by compressed air, 2) Test NIOV system powered by 100% oxygen, 3) nasal cannula oxygen, 4) nothing (Control). Subjects were assessed during constant work rate exercise as reflected by exercise duration, isotime oxygenation (SpO2), and isotime dyspnea score (Borg). Exercise sessions took place over 4 visits with each visit lasting approximately 5 hours.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
15
Inclusion Criteria
  • Adult males, ≥ 40 years of age
  • Diagnosis of severe COPD (GOLD stage III or IV) defined as having a FEV1 < 50% of predicted and an FEV1/FVC ratio < 70% of predicted
  • Ventilatory limitation to exercise, documented by a VE/MVV > 0.85
  • SpO2 between 80% and 88% during incremental exercise testing on room air
  • Willingness and ability (after training) to exercise on a cycle ergometer
  • Willingness and ability to perform all other study related procedures and tasks
  • Ability to be properly fitted with the Breathe nasal mask
  • Ability to tolerate and be appropriately titrated on the Breathe ventilator (See Appendix E)
  • Ability to be properly fitted with an exercise mask
  • Fluency in written and spoken English
  • Provision of written informed consent
Exclusion Criteria
  • History of acute exacerbation of COPD within 30 days of screening
  • History of serious epistaxis within 14 days of screening
  • Requirement of > 5 LPM nasal O2 to maintain an SpO2 > 90% while at rest
  • History of pneumothorax secondary to lung bullae
  • History of intolerance to supplemental oxygen
  • Musculoskeletal or other non-pulmonary impairment that limits exercise tolerance
  • Inability to achieve an optimal CWR level (4-7 minutes) during Study Visit 1R
  • Current participation in another interventional study or participation within 14 days of screening
  • Presence of any condition or abnormality that in the opinion of the Principal Investigator may compromise the subject's safety or the quality of the study data

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
NIOV - Room airNIOV - Room AirSubjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
NIOV - OxygenNIOV - OxygenSubjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
Nasal Cannula OxygenNasal Cannula OxygenSubjects exercise using a standard nasal cannula using medical oxygen (100% O2).
Primary Outcome Measures
NameTimeMethod
Exercise Duration for Constant Work Rate Exercise Tests Under 4 Test ConditionsStudy days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxygen and Nasal Cannula Oxygen.

Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control).

Secondary Outcome Measures
NameTimeMethod
Borg Dyspnea Score During Constant Workrate Exercise at IsotimeOutcome was measured in each Study day 1,2,3 and 4. Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxygen and N

Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control) at isotime. Borg Dyspnea Score ranges in values from 0 to 10. The lower score represent better outcome.

0 = No breathlessness at all, representing better outcome 10 = Maximum breathlessness, representing worse outcome

SpO2 During Constant Workrate Exercise at IsotimeOutcome was measured in each of the Study day 1,2, 3 and 4. Study days 1,2,3, and 4; Day 1 for no treatment; day 2 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 3 for no treatment and NIOV - Room Air and NIOV - oxygen; Day 4 for NIOV - oxyg

Mean differences between NIOV - oxygen, NIOV - Room Air, Nasal Cannula Oxygen, and no treatment (control).

Trial Locations

Locations (1)

Harbor-UCLA Medical Center

🇺🇸

Torrance, California, United States

© Copyright 2025. All Rights Reserved by MedPath